NCT07286331 2026-03-11
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
GlaxoSmithKline
Phase 3 Not yet recruiting
Clinical Trials
21 trialsNCT07418749 2026-02-18
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT07286162 2026-01-27
CALM-TF
University Health Network, Toronto
Phase 3 Not yet recruiting
NCT07286266 2025-12-16
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT05077215 2025-12-08
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Evergreen Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT06476639 2025-11-28
ANVU
Queensland Centre for Gynaecological Cancer
Phase 3 Not yet recruiting
NCT07230626 2025-11-17
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT06839092 2025-07-30
PROPAC
University Hospital, Geneva
Phase 3 Not yet recruiting
NCT07068464 2025-07-16
ICRA
NHS Grampian
Phase 3 Not yet recruiting
NCT06990503 2025-05-25
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT06980545 2025-05-20
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Assiut University
Phase 3 Not yet recruiting
NCT06870565 2025-03-17
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Not yet recruiting
NCT06867562 2025-03-10
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
Jina Pharmaceuticals Inc.
Phase 3 Not yet recruiting
NCT06751485 2024-12-31
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Not yet recruiting
NCT06542549 2024-08-07
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Anhui Provincial Hospital
Phase 3 Not yet recruiting
NCT06539091 2024-08-06
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Anhui Provincial Hospital
Phase 3 Not yet recruiting
NCT06475599 2024-06-27
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06248749 2024-02-08
Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer
University of Saskatchewan
Phase 3 Not yet recruiting
NCT06188455 2024-01-03
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
The First Affiliated Hospital of Xiamen University
Phase 3 Not yet recruiting
NCT05524389 2022-11-23
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
Peking Union Medical College Hospital
Phase 3 Not yet recruiting
NCT04515602 2020-08-27
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
Shanghai Gynecologic Oncology Group
Phase 3 Not yet recruiting